key: cord-0020999-hddzf00e
authors: nan
title: Department of Error
date: 2020-11-26
journal: Lancet
DOI: 10.1016/s0140-6736(20)32479-x
sha: 21a5705fe6c9fb6bd007b9aedfc7f5ba1620003e
doc_id: 20999
cord_uid: hddzf00e

nan

based on results of the phase 2 dosefinding study.

We agree with Uppal and colleagues that young patients (≤30 years old) with vitiligo are reported to have a higher psychosocial burden than older patients (>30 years old), and that there is generally equal representation among individuals with fair skin and dark skin. 2 Patient age (majority >30 years) and the high proportion of patients with fairer skin types are noted as study limitations. 1 Although most patients were white (84%) and had Fitzpatrick skin types I-III (64%), all skin types were represented (32% with Fitzpatrick skin types IV-VI). We are working on a secondary analysis evaluating treatment response by patient demo graphic and clinical characteristic subgroups.

With respect to comments regarding comorbid autoimmune conditions, the study included patients with other autoimmune disorders (most commonly thyroid disease), as described in the baseline characteristics table. 1 The underlying conditions in our study population are representative of the background disorders in patients with vitiligo, and the rates of autoimmune comorbidities were in alignment with those reported in vitiligo chart review studies. 3, 4 No significant safety concerns were noted in our study.

Confirmatory global phase 3 trials of ruxolitinib cream for vitiligo enrolling adolescents and a higher proportion of patients with darker skin types are ongoing (NCT04052425, NCT04057573). These studies will further address safety as well as the generalisability of our findings to a larger patient population. sufficient age and racial representation in research cohorts. Further investigation of ruxolitinib cream is suggested with these specific patient populations in mind.

Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial

Vitiligo update

Vitiligo: a review

Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib

Comorbidities in vitiligo: comprehensive review

We thank Shelley Uppal and colleagues for their comments on the randomised phase 2 trial of ruxolitinib cream for the treatment of vitiligo, 1 in which concerns over the generalisability of the study population were raised. As a phase 2 study, the goal was to evaluate the efficacy and safety of different concentrations and dosing regimens of ruxolitinib cream in patients with non-segmental vitiligo before progressing to phase 3 studies, in which generalisability would be assessed. As such, our study 1 does not state that ruxolitinib cream is a safe and effective treatment for vitiligo or conclude that the study's findings should extend to clinical practice. Instead, we rather suggest that ruxolitinib cream might potentially become an effective treatment option 

Lancet 2020; 396: 1548-49-In this World Report, there was a typo in a quote given by Bernard Pécoul. It should have read: "Fexinidazole is a 10-day long course; we are hoping to be able to launch single-dose treatments for sleeping sickness sometime in the next few years." This correction has been made to the online version as of Nov 26, 2020.